🇺🇸 MEK inhibitor in United States

30 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 28 March 2025 – 28 March 2026
• Total reports: 30

Most-reported reactions

1. Diarrhoea — 4 reports (13.33%)
2. Dyspnoea — 4 reports (13.33%)
3. Hepatic Failure — 4 reports (13.33%)
4. Left Ventricular Dysfunction — 4 reports (13.33%)
5. Hypokalaemia — 3 reports (10%)
6. Sepsis — 3 reports (10%)
7. Anaemia — 2 reports (6.67%)
8. Aphasia — 2 reports (6.67%)
9. Electrocardiogram Qt Prolonged — 2 reports (6.67%)
10. Myopathy — 2 reports (6.67%)

Source database →

Frequently asked questions

Is MEK inhibitor approved in United States?

MEK inhibitor does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for MEK inhibitor in United States?

Craig L Slingluff, Jr is the originator. The local marketing authorisation holder may differ — check the official source linked above.